Mirdametinib plus vinblastine for untreated low-grade glioma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs (mirdametinib and vinblastine) for children and young adults with a type of slow-growing brain tumor called low-grade glioma that has certain genetic changes. It may be an option for people who have not received any previous treatment for their tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 2 to 25 years old
- Diagnosed with a slow-growing brain or spinal cord tumor (low-grade glioma) that has certain genetic changes (like NF1 or a BRAF fusion, but not the BRAF V600E mutation)
- Able to swallow pills whole (not through a feeding tube)
- No prior chemotherapy or radiation for this tumor
- Acceptable blood counts, heart function, and kidney function, and no active infections like HIV or hepatitis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests mirdametinib, a targeted medicine, in children and young adults with low-grade glioma (a slower-growing brain tumor). It aims to find the best dose and see how well the treatment works, especially for tumors with certain “MAPK pathway” changes.
This trial tests a drug called mirdametinib for people with specific types of brain tumors or neurohistiocytosis (a rare condition affecting the nervous system). The drug targets mutations that cause these conditions to grow.
This trial is testing a combination of two drugs, vinblastine and tovorafenib, for children and young adults (up to age 25) whose low-grade glioma has come back or worsened after prior treatment. It is for people whose tumor has a specific change in a gene called BRAF or CRAF.
This trial tests a drug called mirdametinib, which targets a protein linked to tumor growth, given alone or with radiation. It is for people with certain brain or spinal cord tumors, especially those with a condition called NF1, to see if it can help control the cancer.
This Phase 2 trial studies whether a targeted medicine that blocks MEK can work better than chemotherapy for certain slow-growing brain tumors in children. You may qualify if your tumor has specific genetic features and has not already been treated with non-surgery therapies.
This trial tests a new targeted medicine (FCN-159) against standard chemotherapy for children with slow-growing brain or nervous system tumors that have a specific genetic change (BRAF alteration). The goal is to see if the new pill works better at shrinking or controlling the tumor.
Hear when a new Pediatric Low-grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.